Differential beta-adrenoblocker therapy in chronic heart failure

Abstract

Optimal pharmacotherapy of chronic heart failure (CHF) is essential for clinical outcome improvement. Recently, beta-adrenoblockers (BAB) have been regarded as first-line medications in CHD management. At the same time, their significant heterogeneity points to the need of differential administration, taking into account individual clinical features. The benefits of therapy with nebivolol, a BAB with vasodilatator activity, in most CHF patients are demonstrated.

Keywords

• chronic heart failure
• beta-adrenoblockers
• nebivolol